Welcome to our dedicated page for Webster Financial SEC filings (Ticker: WBS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Webster Financial’s 200-plus page annual report to find loan-loss provisions or HSA Bank performance shouldn’t drain an afternoon. Yet bank filings weave regulatory capital tables, credit quality trends, and regional deposit data into dense narratives. If you’ve ever Googled “Webster Financial insider trading Form 4 transactions� or hunted for a single footnote on net interest margin, you know the challenge.
Stock Titan solves it. Our AI combs every Webster Financial quarterly earnings report 10-Q filing, flags key moves, and presents plain-English summaries so you can focus on decisions, not page counts. Need “Webster Financial Form 4 insider transactions real-time�? We alert you the moment executives trade. Wondering about material credit events? Check the “Webster Financial 8-K material events explained� card for context minutes after EDGAR posts. From “understanding Webster Financial SEC documents with AI� to a Webster Financial annual report 10-K simplified, insights arrive as the filings do—no refresh required.
Dig deeper: our platform ties each filing type to what matters for this regional bank. The 10-K highlights deposit mix shifts; the 10-Q tracks quarterly net charge-offs; the proxy spells out “Webster Financial proxy statement executive compensation� against return-on-assets; and the dashboard compiles “Webster Financial earnings report filing analysis� across all segments. With AI-powered redlining, cross-document search, and exportable tables, you’ll quickly spot “Webster Financial executive stock transactions Form 4� before rate decisions move the market. Complex banking disclosures, explained simply and delivered in real time.
Kiniksa Pharmaceuticals (KNSA) delivered its first profitable Q2. Net product revenue rose 44% YoY to $156.8 m on continued uptake of ARCALYST, lifting six-month sales 56% to $294.6 m. Cost of goods remained low (Q2 COGS 12% of sales), sustaining an ~88% gross margin.
Operating expenses grew 26% to $136.6 m, driven by collaboration spend linked to Genentech and Huadong agreements, but leverage from higher revenue pushed operating income to $20.2 m (-$0.1 m LY). After $5.0 m tax, Q2 net income reached $17.8 m (diluted EPS $0.23) versus a $3.9 m loss a year ago; six-month net income was $26.4 m.
Liquidity strengthened: cash, cash equivalents and U.S.-Treasury investments increased to $307.8 m (up $64 m since year-end) aided by $50.4 m operating cash flow and a $20 m milestone from Huadong. Total assets stand at $661.1 m with equity of $495.0 m; inventory rose to $53.0 m as the company pre-positions ARCALYST supply ahead of a manufacturing tech-transfer approval.
Strategic updates: 1) Redomiciliation from Bermuda to the U.K. completed in 2024; 2) April 2025 termination of the Huadong mavrilimumab license eliminates up to $576 m of potential milestones; 3) Remaining upside includes $570 m in potential Genentech milestones (vixarelimab) and $50 m in ARCALYST sales milestones from Huadong, plus mid-teens royalty streams.
The company expects current liquidity to fund operations for �12 months.
Diamond Hill Investment Group (DHIL) filed its Q2-25 10-Q showing mixed operating performance but sharply higher bottom-line results, driven by investment gains. Revenue slipped 2% to $36.0 m as average advisory fee rate fell to 0.44% and equity outflows persisted, partially offset by higher fixed-income assets. Operating expenses rose 15%—mainly a $3.0 m swing in deferred-comp expense—pushing net operating income down 36% to $7.8 m and cutting the GAAP operating margin to 22% (adj. 30%).
Non-operating items reversed the picture. A $14.6 m mark-to-market gain on company investments (vs. a $0.7 m loss last year) lifted net income attributable to common shareholders 92% to $15.6 m, or $5.73 per diluted share (+96%). Assets under management rose 3% YoY to $30.1 bn, aided by $0.9 bn market appreciation that outweighed $0.6 bn net outflows; fixed-income strategies grew 53% while U.S. equity shrank 9%. Cash climbed to $49.1 m, no debt is outstanding on the $25 m credit line, and the board declared a $1.50 quarterly dividend (�$4.1 m) payable 12 Sep 25. During 1H-25 the company repurchased $11.9 m of shares and issued new restricted stock, increasing outstanding shares to 2.73 m. Operating cash flow was �$15.7 m, reflecting incentive payouts and seed capital for consolidated funds, whose non-controlling interest now stands at $23.5 m.
Kratos Defense & Security Solutions, Inc. (KTOS) insider Steven S. Fendley has filed a Form 144 notice to sell additional company stock.
- Proposed transaction: 7,000 common shares, estimated value $409,722.60, through Fidelity Brokerage Services on or after 28 Jul 2025.
- Share-base impact: The sale equals roughly 0.005% of the 152.84 million shares outstanding.
- Source of shares: Grant received 4 Jan 2024.
- Recent activity: Fendley has already sold 36,000 shares in the past three months, generating ~$1.33 million in gross proceeds.
The filer affirms no undisclosed adverse information and acknowledges Rule 10b5-1 liability. The filing signals continued insider liquidity but remains small relative to KTOS’s float.
Lumentum Holdings Inc. (LITE) � Form 144 filing discloses that insider Wupen Yuen intends to sell 265 common shares on 07/23/2025 through Morgan Stanley Smith Barney, valued at $26,478.80. The shares were acquired as restricted stock on 07/20/2024. Lumentum has 69.4 million shares outstanding; the proposed sale represents roughly 0.0004 % of total shares, posing no dilution risk.
The filing also lists Yuen’s prior sales over the last three months totaling 14,675 shares for gross proceeds of about $456 k, equal to �0.02 % of shares outstanding. No Rule 10b5-1 plan adoption date is provided. The standard representation states the seller is unaware of undisclosed adverse information.
Overall, the notice signals routine liquidity activity rather than a material corporate event, but it adds to a pattern of modest ongoing insider sales that some investors may monitor for sentiment.
Cencora, Inc. (COR) � Form 4 filing: President & CEO Robert P. Mauch exercised 3,225 stock options at an $86.09 strike price and concurrently sold 4,968 common shares on 07/18/25 under a Rule 10b5-1 trading plan. The sale was executed at an average $294.11, generating about $1.46 million in gross proceeds.
After the paired exercise-and-sale, Mauch’s direct share ownership fell from 44,094 to 42,351 shares, a net reduction of 1,743 shares (�4%). He continues to hold 25,802 fully vested options. No operational metrics, guidance, or other corporate developments are disclosed; the filing strictly documents routine insider transactions.
Banco de Chile (BCH) Form 6-K � Local bond placement
On 22 Jul 2025 the bank informed the Chilean Financial Market Commission that it completed a domestic offering of three series of senior, dematerialized, bearer bonds:
- Series GB: CLF 500,000, maturity 1 Sep 2034, average placement rate 3.11%.
- Series GG: CLF 150,000, maturity 1 May 2035, average placement rate 3.11%.
- Series HW: CLF 450,000, maturity 1 Jun 2044, average placement rate 3.19%.
The combined issuance totals CLF 1,100,000, providing Banco de Chile with medium- to long-term funding at fixed rates slightly above 3%. All tranches are duly registered with the CMF. The filing contains no additional financial results, guidance, or intended use of proceeds.
Webster Financial Corp. (WBS) � Form 144 notice
An insider intends to sell up to 3,250 common shares through Fidelity Brokerage Services on the NYSE around 22 Jul 2025. Based on the filing’s aggregate market value of $196,007.50, the implied price is roughly $60.31 per share. The transaction equals less than 0.002 % of WBS’s 168.2 million shares outstanding.
The stock to be sold was acquired via six restricted-stock vesting events between May 2022 and May 2024, all classified as compensation rather than open-market purchases. The filer reports no sales during the past three months and certifies awareness of no undisclosed material adverse information. Form 144 is only a notice; the actual sale may be reduced, delayed, or cancelled.
Given the very small size relative to float and typical insider diversification motives, the filing is unlikely to be financially material but may be tracked by investors who monitor insider sentiment.
Webster Financial Corp. (NYSE: WBS) filed an 8-K announcing a senior accounting leadership change. Executive Vice President & Chief Accounting Officer (CAO) Albert J. Wang will resign effective 2 Sep 2025 to pursue another opportunity but will remain through that date to support an orderly hand-off.
Succession plan: Beginning 3 Sep 2025, Gregory S. Madar—currently Senior Managing Director & Corporate Controller—will serve as Interim CAO while the company conducts an internal and external search for a permanent replacement. Madar joined the Bank in 2011, previously holding CAO (2011-17) and HSA Bank CFO (2017-23) roles, providing continuity and institutional knowledge. His interim compensation package has not yet been determined.
No financial results, guidance, or other material transactions were disclosed. The filing is limited to the leadership transition under Item 5.02 and an exhibit index for the Inline XBRL cover page.
Webster Financial Corp. (WBS) insider Daniel Bley has filed a Form 144 indicating intent to sell up to 3,000 common shares through Fidelity Brokerage Services on or after 07/21/2025. The planned sale carries an estimated market value of $183,366, compared with the company’s 168.2 million shares outstanding, representing a de minimis 0.002% of shares.
The shares were originally acquired via restricted-stock vesting on 02/22/2020 (2,695 shares) and 02/24/2020 (305 shares) as compensation. Over the past three months Bley has already sold 4,200 shares in three transactions, generating gross proceeds of $209,769. Including the proposed sale, his cumulative 2025 disposition would reach 7,200 shares.
Form 144 filings signal potential insider activity but do not guarantee execution. Given the tiny percentage of outstanding shares involved, market impact is expected to be limited; however, investors often monitor insider selling for sentiment clues.
Webster Financial Corp. (WBS) � Form 144 notice of proposed insider sale. An unnamed insider plans to sell 2,500 common shares through Fidelity Brokerage on or after 21 Jul 2025. The shares were acquired via restricted-stock vesting on 1 Mar 2025 and represent roughly 0.0015 % of the 168.2 million shares outstanding. Estimated aggregate market value of the planned sale is $153,017 (about $61.21 per share). No other sales by this person have occurred in the past three months. The filer affirms no undisclosed adverse information and certifies compliance with Rule 144 requirements.
The filing is routine, involves a de-minimis proportion of equity, and does not affect company operations, capital structure, or guidance. Investors typically view such small Rule 144 sales as neutral unless part of a larger pattern.